The operator of South Korea's stock markets has decided to allow traders to resume buying and selling shares of Samsung Biologics.
The company is accused of intentionally breaking accounting rules to inflate its profits.
But the Exchange said Monday, after a meeting of its Corporate Review Committee,... that in the interest of maintaining the company's continuity and transparency -- and to protect investors -- trading will resume today.
The company was suspended a month ago after the findings by the Financial Services Commission.